Innovative genomic and proteomic analysis platform for cell therapy and immuno-oncology
Proteona announced the launch of its latest ESCAPE proteogenomics assay designed specifically for Chimeric Antigen Receptor (CAR) T cell characterisation.
This is the first commercial product designed to characterise both RNA and protein expression levels across thousands of single CAR T cells.
Through the use of simultaneous gene and protein expression analysis, the ESCAPE CAR T assay is able to identify CAR positive cells, measure changes in cytokine expression, deeply phenotype cells through measuring the expression of 25 key cell surface proteins and discover new gene expression patterns important for your research.
Together with Proteona鈥檚 data analysis support, the ESCAPE CAR T assay provides rich information that can be used at all stages of the CAR T workflow, from initial cell collection to post infusion patient monitoring.
The Proteona CAR T assay is based on the Enhanced Single Cell Analysis with Protein Expression (ESCAPE) RNA sequencing technology, which uses DNA-barcoded antibodies to capture proteomic and gene expression data simultaneously at the single cell level.
CAR T cells are a promising therapy against aggressive blood cancers and solid tumors. They are manufactured from T cells, immune cells that are able to recognize specific markers on pathogens or abnormal cells and destroy them.
To manufacture CAR T, human T cells are harvested and then modified to target specific cancer antigens, so that they are able to find and kill cancer cells once infused back to the patient. CAR T manufacturing is a complex process, and there is a large range of variations in patient response in terms of toxicity and efficacy.
It is still not clear what the mechanisms are that determine the safety and functionality of CAR T cell treatment. The new CAR T ESCAPE assay now provides a comprehensive tool to shed light on the complex CAR T mechanisms, opening a new path for the development of safer cell therapies.
Click here for the complete issue.